SU 5402

• Description :

  SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.

• CAS Number :

  [215543-92-3]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  FGFR; PDGFR; VEGFR

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SU-5402.html

• Purity :

  99.86

• Solubility :

  DMSO : ≥ 30 mg/mL

• Smiles :

  O=C(CCC1=C(NC=C1C)/C=C2C(NC3=C\2C=CC=C3)=O)O

• Molecular Formula :

  C17H16N2O3

• Molecular Weight :

  296.32

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sun L, et al. Design, synthesis, and evaluations of substituted 3-[ (3- or 4-carboxyethylpyrrol-2-yl) methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem. 1999 Dec 16;42 (25) :5120-30.|[2]Kachel P, et al. Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC Cancer. 2015 Mar 18;15:140.|[3]Trzcińska-Daneluti AM, et al. RNA Interference Screen to Identify Kinases That Suppress Rescue of ΔF508-CFTR. Mol Cell Proteomics. 2015 Jun;14 (6) :1569-83.|[4]Izikki M, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest. 2009 Mar;119 (3) :512-23.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDGFRβ; VEGFR2/KDR/Flk-1